Humacyte/$HUMA
Humacyte shares are trading higher after the company announced its product Symvess received approval for listing by the U.S. Defense Logistics Agency.
19 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Humacyte
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.
Ticker
$HUMA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
219
ISIN
US44486Q1031
Website
Humacyte Metrics
BasicAdvanced
$358M
-
-$0.65
1.64
-
Price and volume
Market cap
$358M
Beta
1.64
52-week high
$9.79
52-week low
$1.15
Average daily volume
3.9M
Financial strength
Current ratio
3.68
Quick ratio
3.162
Long term debt to equity
215.898
Total debt to equity
228.261
Interest coverage (TTM)
-10.61%
Profitability
EBITDA (TTM)
-103.773
Gross margin (TTM)
-15,934.82%
Net profit margin (TTM)
-15,022.44%
Operating margin (TTM)
-21,470.79%
Management effectiveness
Return on assets (TTM)
-42.82%
Return on equity (TTM)
-249.75%
Valuation
Price to revenue (TTM)
555.422
Price to book
9.94
Price to tangible book (TTM)
9.94
Price to free cash flow (TTM)
-2.849
Free cash flow yield (TTM)
-35.10%
Free cash flow per share (TTM)
-81.09%
Growth
Earnings per share change (TTM)
-35.93%
3-year revenue growth (CAGR)
-27.22%
3-year earnings per share growth (CAGR)
16.92%
What the Analysts think about Humacyte
Analyst ratings (Buy, Hold, Sell) for Humacyte stock.
Bulls say / Bears say
Humacyte's successful commercial launch of Symvess in February 2025, with initial shipments to Level 1 trauma centers and 45 hospitals evaluating the product, indicates strong market adoption potential. (TipRanks)
The company's plan to file an IND with the FDA for first-in-human clinical testing of the small-diameter ATEV in coronary artery bypass grafting later this year demonstrates a robust pipeline and commitment to innovation. (TipRanks)
Insider confidence is evident, with significant stock purchases totaling $803,000 over the past year, suggesting a positive outlook on the company's future. (Simply Wall St)
Humacyte faces substantial doubt regarding its ability to continue as a going concern through November 2025, raising concerns about financial stability. (Nasdaq)
The company reported a net loss of $39.2 million for Q3 2024, with no revenue generated during that period, highlighting ongoing financial challenges. (BioSpace)
Despite a market capitalization of $366.08 million, Humacyte's stock has experienced significant volatility, with a 52-week range from $1.15 to $9.46, indicating potential investor uncertainty. (DirectorsTalk Interviews)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
Humacyte Financial Performance
Revenues and expenses
Humacyte Earnings Performance
Company profitability
Humacyte News
AllArticlesVideos
Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency
GlobeNewsWire·7 days ago
Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting
GlobeNewsWire·1 month ago
Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Humacyte stock?
Humacyte (HUMA) has a market cap of $358M as of July 15, 2025.
What is the P/E ratio for Humacyte stock?
The price to earnings (P/E) ratio for Humacyte (HUMA) stock is 0 as of July 15, 2025.
Does Humacyte stock pay dividends?
No, Humacyte (HUMA) stock does not pay dividends to its shareholders as of July 15, 2025.
When is the next Humacyte dividend payment date?
Humacyte (HUMA) stock does not pay dividends to its shareholders.
What is the beta indicator for Humacyte?
Humacyte (HUMA) has a beta rating of 1.64. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.